1. Home
  2. ALT vs ARTNA Comparison

ALT vs ARTNA Comparison

Compare ALT & ARTNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ARTNA
  • Stock Information
  • Founded
  • ALT 1997
  • ARTNA 1905
  • Country
  • ALT United States
  • ARTNA United States
  • Employees
  • ALT N/A
  • ARTNA N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ARTNA Water Supply
  • Sector
  • ALT Health Care
  • ARTNA Utilities
  • Exchange
  • ALT Nasdaq
  • ARTNA Nasdaq
  • Market Cap
  • ALT 292.0M
  • ARTNA 343.5M
  • IPO Year
  • ALT N/A
  • ARTNA 1996
  • Fundamental
  • Price
  • ALT $3.83
  • ARTNA $33.15
  • Analyst Decision
  • ALT Strong Buy
  • ARTNA
  • Analyst Count
  • ALT 6
  • ARTNA 0
  • Target Price
  • ALT $17.40
  • ARTNA N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • ARTNA 28.6K
  • Earning Date
  • ALT 08-12-2025
  • ARTNA 08-04-2025
  • Dividend Yield
  • ALT N/A
  • ARTNA 3.71%
  • EPS Growth
  • ALT N/A
  • ARTNA 22.07
  • EPS
  • ALT N/A
  • ARTNA 2.17
  • Revenue
  • ALT $20,000.00
  • ARTNA $110,427,000.00
  • Revenue This Year
  • ALT N/A
  • ARTNA $6.86
  • Revenue Next Year
  • ALT $761,880.20
  • ARTNA $4.46
  • P/E Ratio
  • ALT N/A
  • ARTNA $15.28
  • Revenue Growth
  • ALT N/A
  • ARTNA 7.13
  • 52 Week Low
  • ALT $2.90
  • ARTNA $29.45
  • 52 Week High
  • ALT $11.16
  • ARTNA $38.94
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • ARTNA 48.19
  • Support Level
  • ALT $3.35
  • ARTNA $33.00
  • Resistance Level
  • ALT $3.66
  • ARTNA $34.28
  • Average True Range (ATR)
  • ALT 0.19
  • ARTNA 0.66
  • MACD
  • ALT 0.07
  • ARTNA 0.01
  • Stochastic Oscillator
  • ALT 86.18
  • ARTNA 36.90

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ARTNA Artesian Resources Corporation

Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.

Share on Social Networks: